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DNA methylation is implicated in mammalian brain development and plasticity underlying
learning and memory. We report the genome-wide composition, patterning, cell specificity, and
dynamics of DNA methylation at single-base resolution in human and mouse frontal cortex
throughout their lifespan. Widespread methylome reconfiguration occurs during fetal to young
adult development, coincident with synaptogenesis. During this period, highly conserved non-CG
methylation (mCH) accumulates in neurons, but not glia, to become the dominant form of
methylation in the human neuronal genome. Moreover, we found an mCH signature that identifies
genes escaping X-chromosome inactivation. Last, whole-genome single-base resolution 5-
hydroxymethylcytosine (hmC) maps revealed that hmC marks fetal brain cell genomes at putative
regulatory regions that are CG-demethylated and activated in the adult brain and that CG
demethylation at these hmC-poised loci depends on Tet2 activity.
Dynamic epigenetic changes have been observed during brain development, maturation, and
learning (1–6). DNA methylation (mC) is a stable covalent modification that persists in
postmitotic cells throughout their lifetime, defining their cellular identity. However, the
methylation status at each of the ~1 billion cytosines in the genome is potentially an
information-rich and flexible substrate for epigenetic modification that can be altered by
cellular activity (7, 8). Changes in DNA methylation were implicated in learning and
memory (9, 10), as well as in age-related cognitive decline (11). Mice with a postnatal
deletion of DNA methyltransferases Dnmt1 and Dnmt3a in forebrain excitatory neurons, or
with a global deletion of methyl-CpG-binding protein 2 (MeCP2), show abnormal long-term
neural plasticity and cognitive deficits (2, 12).
DNA methylation composition and dynamics in the mammalian brain are highly distinct. A
modification of mC catalyzed by the Tet family of mC hydroxylase proteins, 5-
hydroxymethylcytosine (hmC), accumulates in the adult brain (13–15) along with its more
highly oxidized derivatives 5-formylcytosine and 5-carboxylcytosine. These modifications
of mC were implicated as intermediates in an active DNA demethylation pathway (16–19).
In addition, methylation in the non-CG context (mCH, where H = A, C, or T) is also present
in the adult mouse and human brains (20, 21) but is rare or absent in other differentiated cell
types (22, 23). Little is known about cell type–specific patterning of DNA methylation and
its dynamics during mammalian brain development. Here, we provide integrated empirical
data and analysis of DNA methylation at single-base resolution, across entire genomes, with
cell-type and developmental specificity. These results extend our knowledge of the unique
role of DNA methylation in brain development and function and offer a new framework for
testing the role of the epigenome in healthy function and in pathological disruptions of
neural circuits.
Accumulation of Non-CG DNA Methylation During Brain Development
To identify the composition and dynamics of transcription and methylation during
mammalian brain development, we performed transcriptome profiling (mRNA-Seq) and
whole-genome bisulfite sequencing [MethylC-Seq (24)] to comprehensively identify sites of
cytosine DNA methylation (mC and hmC) and mRNA abundance at single-base resolution
throughout the genomes of mouse and human frontal cortex (table S1). DNA methylation in
embryonic stem (ES) cells occurs in both the CG (mCG) and non-CG (mCH) contexts, but
mCH is largely lost upon cell differentiation (22, 23, 25, 26). We found that although mCH
levels are negligible in fetal cortex, abundant mCH occurs in adult frontal cortex (Fig. 1A).
mCH has previously been identified throughout the genome of the adult mouse brain (20)
and at several hundred genomic positions in the human adult brain (21). Supporting previous
studies, we found that mammalian brain mCH is typically depleted in expressed genes, with
genic mCH level inversely proportional to the abundance of the associated transcript (Fig. 1,
A and B) (20). This pattern is the opposite of that observed in ES cells (22) and suggests that
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genic mCH in the brain may inhibit transcription. The absence of mCH in fetal brain
suggests that this signature for gene repression is added to the genome at a later
developmental stage.
We performed MethylC-Seq on mouse and human frontal cortex during early postnatal,
juvenile, adolescent, and adult stages (Fig. 1C). CH methylation level, defined as the
fraction of all base calls at CH genome reference positions that were methylated (denoted
mCH/CH), accumulates in mouse and human brain during early postnatal development to a
maximum of 1.3 to 1.5% genome-wide at the end of adolescence before diminishing slightly
during aging. mCH increases most rapidly during the primary phase of synaptogenesis in the
developing postnatal brain, from 2 to 4 weeks in mouse (27) and in the first 2 years in
humans (28), followed by slower accumulation of mCH during later adolescence. mCH
accumulation initially parallels the increase in synapse density within human middle frontal
gyrus (synaptogenesis lasts from birth to 5 years), but it subsequently continues to increase
during the period of adolescent synaptic pruning, which in humans occurs between 5 and 16
years of age (Fig. 1C). Notably, the accumulation of mCH in mice from 1 to 4 weeks after
birth coincides with a transient increase in abundance of the de novo methyltransferase
Dnmt3a mRNA and protein (Fig. 1D). Analysis of the context of mCH sites showed that it is
mainly present in the CA context (fig. S1, A to F), as previously reported for mCH (20, 22,
23, 26).
Overall, genomes in the frontal cortex are highly methylated. Whereas CG partially
methylated domains (PMDs) account for about a third of the genome of various
differentiated human cells (22, 25), human brain genomes have negligible CG PMDs,
resembling pluripotent cell methylomes (25) (fig. S1, G and H). Given the high spatial
concordance of CG PMDs and nuclear lamina-associated domains reported previously (29),
the paucity of CG PMDs in these brain methylomes could indicate that lamina-associated
domains are altered or much less frequent in the brain.
The adult mammalian brain contains the highest levels of hmC that have been observed (15),
accounting for about 40% of methylated CG sites in cerebellar Purkinje cells (30). hmC
accumulates during early postnatal brain development in mice (31, 32), becoming enriched
in highly expressed genes (33). Given the evidence that hmC can be an intermediate in an
active DNA demethylation pathway (16, 17), high-resolution analysis of the genomic
distribution of hmC is needed to understand its role in the control of DNA methylation
dynamics through brain development. Standard bisulfite-sequencing data does not
distinguish between methylated and hydroxymethylated sites, so methylcytosines identified
by MethylC-Seq analysis represent the sum of these two contributions. Therefore, we used
Tet-assisted bisulfite sequencing [TAB-Seq (34)], a base-resolution technique that
distinguishes hmC from C and mC genome-wide, to profile hmC in mouse fetal and adult
frontal cortex (Fig. 1A). Integration of the genome-wide profiles of mC and hmC enabled a
detailed breakdown of the methylated subset of the genome at these distinct developmental
stages (Fig. 1E). hmC constitutes 0.20% of total cytosine base calls in fetal cortex and
increases to 0.87% in adult cortex. This modification appears to be restricted to the CG
context, as also observed in human and mouse ES cells (34); after correction for false
detection, we estimated that 0.017% of cytosine base calls were hmCH genome-wide (99%
confidence interval: 0 to 0.059%), and significant hmCH was detected at few individual sites
(fig. S2, A and B). The overwhelming presence of hmC in the CG context (99.98%) in
mouse adult and fetal frontal cortex is consistent with recent findings in human ES cells,
where 99.89% of hmC is in the CG context (34). hmC was present at many highly
methylated CG sites (fig. S2C). Therefore, although only a small fraction of all cytosines
throughout the genome are methylated (mCG = 2.9%, mCH = 1.3%, hmC = 0.87%), mCH
and hmC constitute major, and nonoverlapping, components of the methylated fraction of
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the genome in adult frontal cortex (mCG = 57.2%, mCH = 25.6%, hmC = 17.2%). These
data suggest that the steady-state population of hmC in the adult brain is not an intermediate
stage in the demethylation of mCH. However, these steady-state measurements do not
preclude the possibility that hmCH could be rapidly turned over after conversion from mCH,
leading to negligible detected hmCH despite Tet-mediated demethylation at CH sites.
Protection of Inaccessible Genomic Regions from de Novo Methylation
mCH accumulates in parallel across most of the genome (Fig. 1F). However, we found
numerous (36 in human, 34 in mouse) noncentromeric, megabase-sized regions that do not
accumulate mCH. These regions, which we termed mCH deserts, are enriched for large gene
clusters that encode proteins involved in immunity and receptors required for sensory
neuron function (table S2). One mCH desert spans the immunoglobulin VH locus, which
encodes variable domains of the immunoglobulin heavy chain that rearrange in B
lymphocytes. The VH locus is transcriptionally quiescent in the frontal cortex of 10-week-
old mice, and the chromatin state is highly inaccessible, as inferred from deoxyribonuclease
I (DNaseI) hypersensitivity profiling (35) and chromatin immunoprecipitation (ChIP) input
sequence read density data (36, 37) (Fig. 1G). In contrast, mCG is not depleted in mCH
deserts.
Genome-wide detection of hmC by cytosine 5-methylenesulphonate immunoprecipitation
(CMS-IP) (38, 39) revealed that hmC is also strongly depleted in the VH locus. mCH deserts
are observed at other loci in the genome, including olfactory receptor gene clusters that form
heterochromatic aggregates required for monoallelic receptor expression in olfactory
sensory neurons (40, 41). Genome-wide comparison of mCH/CH with chromatin
accessibility, as inferred from ChIP input read density (36, 37), for all 10-kb windows of the
mouse genome revealed two discrete groups of genomic regions (Fig. 1H). Low-
accessibility regions tend to contain minimal mCH, whereas more-accessible regions of the
genome show a proportional relationship between genome accessibility and mCH levels.
Thus, although mCG is unaffected in these regions, lower chromatin accessibility appears to
be highly inhibitory to deposition of mCH and hmC, potentially via inaccessibility to de
novo methyltransferases and Tet mC hydroxylases. Furthermore, this indicates that
accumulation of mCH and hmC during mammalian brain development occurs via processes
that are at least partly independent from methylation at CG dinucleotides.
Cell Type–Specific DNA Methylation Patterns in Neurons and Glia
The diversity of neuronal and glial cells in the frontal cortex raises the question of which
features of DNA methylation are found in specific cell types. We isolated populations of
nuclei by fluorescence-activated cell sorting that were highly enriched for neurons (NeuN+)
or glia (NeuN−) from human and mouse adult frontal cortex tissue. An additional glial
population was isolated from mice expressing enhanced green fluorescent protein (eGFP)
under the S100b promoter. MethylC-Seq revealed differences in the composition and
patterning of mCG and mCH in neurons and glia (Fig. 2A). Whereas differential mCG
between neurons and glia was restricted to localized regions, neurons were globally enriched
for mCH compared with glia. Indeed, we discovered that the level of mCH in glia is similar
to that of fetal and early postnatal cortical tissue, whereas adult neurons have the greatest
frequency of mCH that has been observed in mammalian cells. This indicates that the rapid
developmental increase in mammalian brain mCH that coincides with the period of
synaptogenesis is primarily due to mCH accumulation in neurons. Furthermore, our data
show that in human neurons mCH is the dominant form of methylation in the genome: It is
more abundant than mCG and occurs in 5% of CH and 10% of CA sites (Fig. 2B and fig.
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S1, A, B, and H). Of the total methylated fraction of adult human neuronal genomes, mCH
accounts for ~53%, whereas mCG constitutes ~47%.
Although sparse in glia, mCH enrichment occurs within genes that are CH-hypomethylated
in neurons, such as Mef2c (Fig. 2A), a transcriptional activator that plays critical roles in
learning and memory, neuronal differentiation (42), synaptic plasticity (43), and regulation
of synapse number and function (44). Genome-wide surveys identified 174 mouse genes in
which glia were hypermethylated relative to neurons in the CH context (table S3). Unbiased
gene ontology analysis revealed that these glial hyper-mCH genes are highly enriched for
roles in neuronal and synaptic development and function (table S3). These genes also
overlapped significantly with a set of 461 genes expressed at higher levels in neurons than in
astrocytes (13-fold higher overlap than chance, P < 10−30, Fisher exact test, FET) (45) and
233 developmentally up-regulated genes (7.5-fold, P < 10−7, FET). These genes show
hypomethylation of CG and CH in neurons and hypermethylation of CH in glia (fig. S3A),
consistent with a potential role of mCH in transcriptional repression of neuronal genes in the
glial genome. Furthermore, genes associated with oligodendrocyte or epithelial function
accumulate mCH through development (fig. S3B), with oligodendrocyte up-regulated genes
showing intragenic mCH hypermethylation in neurons and hypomethylation in glia, whereas
epithelial genes display mCH hypermethylation in both neuronal and glial populations.
Consistent with CH methylation requiring Dnmt3a, glial hyper-mCH genes frequently
intersect areas of the genome bound by Dnmt3a in mouse postnatal neural stem cells (46).
Dnmt3a-binding regions are greatly enriched for mCH, particularly in glia, whereas mCG is
not enriched in Dnmt3a-binding regions in glia and is depleted in neurons (Fig. 2C). Thus,
there is an association with Dnmt3a binding sites specific to mCH and not mCG, suggesting
partial independence between these two marks.
mCH Position Is Highly Conserved
We examined whether the position of DNA methylation is stochastic or precisely controlled
at different genomic scales. The level of mCH in 10-kb windows throughout the genome
was highly reproducible between independent samples of the same cell type, with lower, but
substantial, correlation between cell types (Fig. 2D). Closer inspection revealed consistency
between the methylation level at individual mCH sites in neurons from different individuals
in both mice and humans (Fig. 2E). At single-base resolution (fig. S4), perfect correlation
between individuals would not be observed even if the true methylation level were identical
at each site because of the stochastic effect of a finite number of sequenced reads. To correct
for this, we normalized the observed correlation by that of simulated data sets with the same
coverage per site as each of our experimental samples but with identical methylation levels
(Fig. 2F and fig. S4). To assess statistical significance, we used a permutation test, which
compared the data correlation with the correlation after randomly shuffling the relative
positions of CH sites in each sample (fig. S4). This revealed that autosomal CG and CH sites
have nearly identical methylation levels in neuronal populations isolated from different
individuals of the same species. Observed differences could be explained by stochastic
sampling rather than true individual variation. Unexpectedly, normalized per-site correlation
is higher for mCH than mCG between neuronal populations isolated from the frontal
cortices of different human individuals, and mouse neuronal mCG and mCH per-site
correlations are equivalent. Per-site correlation between two human ES cell lines (H1 and
HUES6) is also high (>0.8) for both mCG and mCH.
The high interindividual correlation of mCH at the kilobase and single-site scales indicates
that methylation of CH positions, particularly in mammalian neurons, is a highly controlled
process. It is not consistent with a stochastic event that takes place at any available CH
position in a particular genomic region that accumulates mCH. Comparison of mCH
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between human and mouse neurons at conserved exonic CH positions revealed a low but
significant interspecies correlation (Fig. 2F; P < 0.005, shuffle test), possibly indicating
conservation of the cellular processes that precisely target or restrict mCH at these positions.
Last, per-site mCG and mCH correlation between human ES cells and neurons is
significantly lower, likely because of differences in the processes governing methylation of
particular genomic features in the distinct cell types, for example, enrichment and depletion
of mCH in highly transcribed genes in ES cells and neurons, respectively (Fig. 1, A and B).
The precise conservation of mCH position may be partly caused by the physical
configuration of DNA within nucleosomes. Consistent with this, neuronal mCH patterns
contain robust periodic components at the scale of nucleosome spacing [~170 base pairs
(bp), fig. S5A] and the DNA helix coil length (~10.5 bp, fig. S5B). Such periodic
components may arise from sequence-dependent constraints on mCH position, which would
be the same in every neuronal cell. Alternatively, epigenetic heterogeneity within the
population of NeuN+ nuclei in our sample may lead to stronger correlation for CH sites
located on the same physical chromosome, compared with the correlation between the same
locations on chromosomes from different cells. To test this, we measured the cross-
correlation within individual reads, revealing a contribution of within-chromosome
correlation to the periodic methylation pattern (fig. S5C).
Gender-Specific DNA Methylation Patterns on the X Chromosome
Interindividual correlation of mCG and mCH on chromosome X (ChrX) is frequently lower
than on autosomes (Fig. 2F), prompting a closer analysis of ChrX mC patterns. ChrX mCG
and mCH levels were generally lower in females compared with males, presumably because
of the effect of ChrX inactivation (fig. S5, F and G) (47, 48). However, a subset of genes in
both humans and mice have significantly greater intragenic mCH levels in females
compared with males (Fig. 3A). Inspection of these genes revealed that most were
previously found to escape inactivation in human females (X-escapees), displaying biallelic
expression (49) and a reduction in promoter mCG hypermethylation, a DNA methylation
signature of inactivated alleles (50). Quantification of human gender differences in neuronal
DNA methylation for ChrX genes previously characterized as showing biallelic expression
(49) revealed that females have reduced promoter mCG and a large increase in intragenic
mCH but not intragenic mCG (Fig. 3, B and C, and fig. S5, D and E). The sequence
composition of mCH is very similar in the whole genome, within autosomal gene bodies,
and within X-chromosome inactivated and escapee gene bodies (fig. S5H). Analysis of
gender-specific methylation in additional human cell types revealed that female promoter
mCG hypomethylation is observed at X-escapee genes in glia and human embryonic stem
cells (fig. S6). Intragenic mCH hypermethylation of X-escapees was also observed in female
glia, albeit to a lesser extent than in neurons, but was not present in ES cells. Thus, X-
escapee mCH hypermethylation may be a feature that is specific to neural cell types.
Although both promoter CG hypomethylation and intragenic CH hypermethylation provide
significant information for discriminating X-escapees [Fig. 3D, discriminability index (area
under the curve, AUC) = 0.75 and 0.78, respectively], combining both mCG and mCH
measurements boosts discriminability (AUC = 0.88). By using this intragenic mCH
hypermethylation signature, we identified seven new putative X-escapee genes (table S4).
On the basis of these data, we hypothesize that intragenic CH hypermethylation in neurons
may play a compensatory role in genes that fail to acquire repressive CG hypermethylation
in the promoter region, restoring equal gene expression between male and female cells (51).
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Distinct Genic DNA Methylation States Demarcate Functionally Relevant
Gene Clusters
DNA methylation within promoter regions and in gene bodies is implicated in regulation of
gene expression (22, 52), suggesting that the precisely conserved, cell type–specific DNA
methylation patterns may be related to specific neuronal and glial cellular processes. We
therefore used an unbiased approach to classify patterns of mCG and mCH within each
annotated gene body and in flanking regions extending 100 kb up- or downstream. After
normalizing the methylation pattern around each autosomal gene by the local baseline mCG
or mCH level in each adult neuronal or glial sample, we combined these features into a large
data matrix containing 4200 individual DNA methylation measurements for each gene
[seven samples, two contexts (CG and CH), 300 1-kb bins within and around each gene].
Using principal component (PC) analysis, we extracted five methylation features (PCs) that
together account for 46% of the total data set variance (fig. S7A). Gene sets with specific
neuronal or astrocytic expression, as well as ChrX genes, segregate within PC space (fig.
S6B). We then used k-means clustering to classify all genes into 15 clusters on the basis of
their mCG and mCH patterns (Fig. 4A and fig. S8). Several dominant patterns of DNA
methylation and transcript abundance and dynamics between developmental and cellular
states are evident. A cluster of genes that progressively loses gene-body mCG and mCH
through development contains constitutively highly expressed genes that are strongly
enriched for neuronal function and depleted for astrocyte-specific roles (Fig. 4A, box 1).
These genes show intragenic mCG enrichment in glia and depletion in neurons (box 2),
indicating that glial gene body mCG resembles that of the neural precursor cells that
predominate the fetal brain. This indicates that the loss of mCG in brain tissue during
development is due to CG hypomethylation in mature neurons. These constitutively highly
expressed genes enriched for neuronal function also show extensive intragenic mCH
hypomethylation in neurons in contrast to glia (box 3), and they are enriched for hmCG (box
4) as previously described (32, 33). Genes that are not as highly transcribed, but that are
associated with neuronal function and are developmentally up-regulated, also show
intragenic mCG and mCH hypomethylation in neurons but not glia (box 5). For these gene
sets, mCG and mCH enrichment or depletion is precisely localized to transcribed regions,
suggesting that this modification of genic mC is tightly coupled to transcription. Notably,
the bodies of constitutively high genes that are not enriched for neuronal function (box 6) do
not show marked fetal/glial mCG enrichment or neuronal mCH depletion, indicating that
this differential methylation is specific for genes enriched for neuronal function and not
simply an association with particular levels of transcriptional activity. Genes associated with
astrocyte function show an opposite pattern to genes associated with neuronal function: a
progressive increase in intragenic mCG and mCH in frontal cortex tissue over development,
neuronal mCG and mCH hypermethylation, and glial mCG and mCH hypomethylation (Fig.
4A, boxes 7 to 9). Last, genes with constitutively low expression do not show developmental
or cell type–specific DNA methylation patterns (box 10), demonstrating that dynamic DNA
methylation in genes is highly associated with differential transcriptional activity in
mammalian brain development and neural cell specialization.
Each of the gene clusters identified in our unbiased analysis was significantly enriched or
depleted for cell type–specific function [neuronal or astrocytic genes (45)] or particular
expression patterns (constitutively high or low expression, developmentally up- or down-
regulated) (Fig. 4B). Profiling the median mCG and mCH of genes within each of these
categories allows direct comparison of developmental and cell type–specific DNA
methylation in mouse (Fig. 4C) and human (fig. S3C). This analysis recapitulates many of
the conclusions of the unbiased clustering (Fig. 4A).
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The inverse relationship observed between genic mCH level and transcriptional activity is
consistent with a model whereby intragenic accumulation of mCH impedes transcriptional
activity. Alternatively, the process of transcription could interfere with mCH de novo
methylation or induce active mCH demethylation, although these are not consistent with the
DNMT3A-dependent intragenic mCH in human embryonic stem cells that is positively
correlated with gene expression (22, 23). Overall, glial mCG and mCH patterns closely
resemble those of the fetal and the early postnatal brain, indicating that DNA methylation in
early mammalian brain developmental stages may be a default state that largely persists
through to maturity in glial cells, whereas neuronal differentiation and maturation involve
extensive reconfiguration of the DNA methylome that is highly associated with cell type–
specific changes in transcriptional activity.
hmCG Is Enriched Within Active Genomic Regions in Fetal and Adult
Mouse Brain
Our base-resolution analysis of hmC using TAB-Seq revealed that intragenic and global
hmCG levels are largely equivalent between chromosomes, whereas hmCG/CG is 22%
lower on the male ChrX, consistent with previous reports from enrichment based detection
of hmC (32, 33) (Fig. 5A). Analysis of hmCG levels in different genomic regions revealed
that, although adult hmCG/CG is similar across transcriptional end sites and intragenic,
DNaseI-hypersensitive (DHS), and enhancer regions, the fetal frontal cortex shows a relative
enrichment of hmCG in DHS regions and enhancers, in particular enhancer regions that are
unique to the fetal developmental stage (Fig. 5B). The inverse pattern can be observed for
adult mCG levels, which are lower in DHS regions and enhancers (fig. S9, A and B),
suggesting that regions of relatively high hmCG levels in the fetal brain show relatively low
mCG levels in the adult brain. Analysis of intragenic hmCG enrichment relative to flanking
genomic regions, for cell type–specific or developmentally dynamic gene sets (Fig. 5C),
showed that neuronal and astrocyte gene bodies that are highly enriched with hmCG in adult
are also highly enriched at the fetal stage.
Thus, despite lower absolute levels of intragenic hmCG in the fetal stage, the adult patterns
of hmCG enrichment at these cell type–specific genes are already forming in utero.
Constitutively lowly expressed genes show intragenic depletion of hmCG, in contrast to
constitutively highly transcribed genes, which show localized enrichment of hmCG
throughout part or all of the gene body. Developmentally down-regulated genes show
enrichment of hmCG in the fetal frontal cortex but not in adults, indicating that reduced
transcription is accompanied by a loss of hmCG enrichment. Overall, transcriptional activity
is associated with intragenic hmCG enrichment, as reported (33), with in utero establishment
of adult hmCG patterns for cell type–specific genes and loss of hmC enrichment associated
with developmentally coupled transcriptional down-regulation.
Measurement of mC and hmC in all genes in fetal and adult mouse frontal cortex indicated
that both mCG and hmCG are depleted at promoters and in gene bodies of lowly expressed
genes, whereas hmCG is enriched throughout the gene bodies of more highly transcribed
genes (Fig. 5D). The most highly expressed genes in the adult frontal cortex show intragenic
mCG hypomethylation (Figs. 4 and 5D) but still retain high intragenic hmCG. Ranking all
genes by transcript abundance, it is evident that the highest mean intragenic hmCG levels,
which occur in the most highly transcribed genes, correspond to hmCG/CG ~ 0.25 and
mCG/CG ~ 0.5 (fig. S10D). Frontal cortex development is accompanied by increased
enrichment of hmCG at intragenic regions that are already hyper-hydroxymethylated at the
fetal stage (Fig. 5D and fig. S10), demonstrating that adult patterns of genic hmC are already
evident in the immature fetal brain.
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CG Differentially Methylated Regions Enriched in Regulatory Regions
Because differences in genic mCG were observed over development and between neuronal
and glial cell populations (Fig. 4), we scanned the human and mouse methylomes to
comprehensively identify CG differentially methylated regions (CG-DMRs) throughout the
genome. CG-DMRs were identified between fetal and adult frontal cortex, neurons and glia,
and combined into four sets: neuronal and glial hyper- and hypo-methylated CG-DMRs. In
total, 267,799 human and 142,835 mouse CG-DMRs were identified (median lengths: for
mouse, 473 bp; human, 533 bp), revealing several predominant dynamics in mCG during
brain development and cellular specialization (Fig. 6A and fig. S11). Neuronal CG-DMRs
are the most numerous in both mice and humans, because of the very distinct mCG patterns
that emerge during neuronal differentiation and maturation. At these sites, CG methylation
in adult neurons is distinct compared with those in glial and/or fetal and early postnatal
development frontal cortex tissue samples. Neuronal hypermethylated CG-DMRs also show
mCH hypermethylation (fig. S11). In mouse, mCG/CG within neuronal hypomethylated
CG-DMRs declines to a stable level by 1 week after birth. In contrast, neuronal
hypermethylated CG-DMRs do not begin to change until 1 week after birth, after which they
accumulate mCG until 2 to 4 weeks of age. These data indicate that increases in neuronal
mCG occur during synaptogenesis after most decreases in neuronal mCG have already
occurred. Furthermore, we found that hydroxymethylation in the adult cortex is highest in
CG-DMRs that show neuronal hypermethylation and is depleted from CG-DMRs that
display neuronal hypomethylation (Fig. 6A). This suggests that hmCG may be most
abundant in neurons, rather than glial cells, in the frontal cortex.
Analysis of the genomic features in which CG-DMRs are located revealed that although half
are found within gene bodies, they are not common within promoters and transcriptional
start and end regions. Instead, they are disproportionately located at DHS regions and
enhancers unique to fetal or adult brain (Fig. 6B). Closer inspection of the enrichment and
depletion of these CG-DMRs revealed that fetal enhancers and DHS sites unique to the fetal
brain are enriched for hypermethylation in adult brain but not in the fetal brain (Fig. 6C). In
contrast, adult enhancers and unique adult DHS sites are highly associated with CG
hypermethylation in fetal stages but are not associated with hypermethylated CG-DMRs in
the adult brain and in neurons. Thus, developmentally dynamic enhancers and DHS sites in
frontal cortex have dynamic CG methylation that is depleted where chromatin accessibility
and regulatory element activity increase, consistent with a range of human cell lines (53).
To characterize gene functions associated with the CG-DMRs, we analyzed the association
between proximal genes (transcriptional start site within 5 kb of the DMR) and cell type–
specific or developmentally dynamic gene sets (fig. S12A). We observed an inverse
relationship between methylation and gene function. Genes associated with neuronal
function and up-regulation during development are enriched for promoter hypermethylation
in glia and hypomethylation in neurons, whereas genes down-regulated during brain
development and those related to astrocyte function are enriched for promoter
hypermethylation in neurons and hypomethylation in glia. Genes that are constitutively
expressed at either high or low levels are not associated with promoter/transcription start site
CG-DMRs, indicating that dynamic CG methylation is highly associated with changes in
transcriptional activity and cell type–specific transcriptional regulation.
Because the majority of all developmentally dynamic CG-DMRs are associated with DHS
sites, we examined the directional relationships between dynamic mCG and DNA
accessibility states over development (Fig. 6D). Notably, DHS sites unique to fetal frontal
cortex overlap with 28% of CG-DMRs that gain methylation through development
(Adult>Fetal). However, these sites only overlap 7.3% of CG-DMRs that lose mCG during
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development (Fetal>Adult). Similarly, DHS sites unique to adult frontal cortex rarely
overlap Adult>Fetal CG-DMRs. A similar analysis of developmentally dynamic enhancers
active in only one of the developmental stages (37) (Fig. 6E) showed that enhancer
activation is associated with mCG hypomethylation of the enhancer, whereas enhancer
inactivation is associated with enhancer mCG hypermethylation.
This inverse relationship between genome accessibility and mCG level at putative functional
regions of the genome suggests that nuclear factors that bind the region and increase
accessibility may cause localized reduction in mCG, as previously reported for a small
number of DNA binding proteins (54). Alternatively, mCG hypermethylation may cause
reduced genome accessibility by direct inhibition of DNA-protein interactions or induction
of chromatin compaction, with loss of mCG enabling increased chromatin accessibility and
genome interaction with DNA binding factors.
Discrete regions that show increased or decreased CG methylation through development are
associated with specific local chromatin modifications. We found that CG-methylated
regions of the fetal frontal cortex that become hypomethylated in the adult (Fig. 6F,
Fetal>Adult) gain localized histone modifications characteristic of active enhancers
(H3K4me1 and H3K27ac) and increased DNaseI hypersensitivity in the adult. In addition,
these regions have reduced accumulation of mCH (Fig. 6F), consistent with an overall
decrease in mC linked to increased genome accessibility and enhancer activity. In contrast,
genomic regions that gain mCG during development (Adult>Fetal) lose localized
enrichment of H3K4me1, H3K27ac, and DNaseI hypersensitivity and show increased mCH.
These changes indicate inactivation of these genomic regions through brain development
and suggest that this inactivation is associated with increased local mCG.
A Hydroxymethylation Signature of Developmentally Activated Regions
Adult>Fetal CG-DMRs show broad low-level hmCG enrichment flanking the CG-DMR and
a localized depletion of hmC at the center in both fetal and adult genomes (Fig. 6F), and the
absolute abundance of hmC is several-fold lower in fetal compared with adult frontal cortex
(Fig. 1E). This suggests that although Adult>Fetal CG-DMRs gain mCG through
development, they tend to be refractory to conversion to hmC, potentially because of lower
accessibility to the Tet hydroxylases. In contrast, Fetal>Adult CG-DMRs have a local
enrichment of both mCG and hmCG in the fetal cortex that becomes a local depletion in the
adult. Two enrichment-based genome-wide hmC profiling techniques, CMS-IP (38) and
biotin-glucosyl tagging (31), confirmed the localized enrichment of hmC at Fetal>Adult
CG-DMRs (fig. S12B). The localized enrichment of hmC at these inaccessible and quiescent
genomic regions, which lose mCG and hmCG later in development, indicates that they may
be premodified with hmCG in the fetal stage to create a dormant state that is poised for
subsequent demethylation and activation at a later developmental stage. Closer inspection of
base-resolution hmC data revealed that 4% of the hmCG bases that have significantly higher
hmC levels in fetal compared with adult [false discovery rate (FDR) 0.05] directly overlap
with Fetal>Adult CG-DMRs, far exceeding the number expected by chance (0.5%). This
indicates that despite lower global levels of hmC in the fetal brain, developmentally
demethylated CG-DMRs are enriched for hmCG bases that are more highly
hydroxymethylated in fetal than in adult brain (Fig. 6G). The localized enrichment of mCG
at these CG-DMRs in the fetal cortex indicates that CG-demethylation has not yet taken
place.
If fetal hmCG is poised at dormant genomic regions in order to facilitate active DNA
demethylation at later developmental stages, then the Tet hydroxylase enzymes that catalyze
conversion of mC to hmC should be necessary for mCG hypomethylation in the adult frontal
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cortex at these regions. To test this, we performed MethylC-Seq of genomic DNA from
frontal cortex tissue of adult Tet2−/− mice. Adult>Fetal CG-DMRs, which gain mCG
through development, are largely unaffected in Tet2−/− compared with wild-type adult mice
(Fig. 6, H and I; 3.6% hypermethylated, FET, FDR 0.05). By contrast, a substantial fraction
of Fetal>Adult CG-DMRs are hypermethylated in Tet2−/− (19.7%) versus wild type. The
mutant shows a small but significant increase in mCG at Fetal>Adult CG-DMRs (Fig. 6I
and fig. S12C) (Tet2−/−: 7.9% ± 4.6%, P < 10−11, Wilcoxon signed rank test). The partial
effect of the mutation on CG methylation is not unexpected given that all three Tet genes are
expressed in the brain (fig. S9C) and may exhibit some functional redundancy. Additionally,
a genome-wide search identified 14,340 CG-DMRs hypermethylated in Tet2−/− relative to
wild type (6 weeks, 10 weeks, and 22 months), >fourfold more numerous than
hypomethylated CG-DMRs (3099). This further indicates a role for Tet2 in mediating mCG
demethylation during brain development.
Discussion
The essential role of frontal cortex in behavior and cognition requires the coordinated
interaction, via electrical and chemical signaling, of multiple neuronal cell types and a
diverse population of glial cells. Individual brain cells have unique roles within circuits that
are defined by their location and pattern of connections as well as by their molecular
identity. The development and maturation of the brain's physical structure and the
refinement of the molecular identities of neurons and glial cells occur in parallel in a finely
orchestrated process that starts early during the embryonic period and continues, in humans,
well into the third decade of life (55, 56). An early postnatal burst of synaptogenesis is
followed by activity-dependent pruning of excess synapses during adolescence (28, 57, 58).
This process forms the basis for experience-dependent plasticity and learning in children and
young adults (59), and its disruption leads to behavioral alterations and neuropsychiatric
disorders (60). During this period, profound transcriptional changes lead to the appearance
of adult electrophysiological characteristics in neocortical neurons.
Our study suggests a key role of DNA methylation in brain development and function. First,
CH methylation accumulates significantly in neurons through early childhood and
adolescence, becoming the dominant form of DNA methylation in mature human neurons.
This shows that the period of synaptogenesis, during which the neural circuit matures, is
accompanied by a parallel process of large-scale reconfiguration of the neuronal epigenome.
Indeed, central nervous system deletion of Dnmt3a during late gestation induces motor
deficits, and animals die prematurely (61). However, mice with a postnatal deletion
restricted to the pyramidal cell population (complete recombination around 1 month old) do
not show overt behavioral or transcriptional alterations (2). Our data suggest that expression
of Dnmt3a specifically around the second postnatal week may be critical for establishing a
normal brain DNA methylation profile and allowing healthy brain development.
Second, the precise positioning of mCG and mCH marks, which are conserved between
individuals and across humans and mice, is consistent with a functional role. Whether this is
the case, or whether the conserved patterns are instead a reflection of conserved nucleosome
position or chromatin structure, requires further investigation. Third, the relationship
between DNA methylation patterns and the function of neuron- or astrocyte-specific gene
sets suggests a role for DNA methylation in distinguishing these two broad classes of
cortical cells. DNA methylation could therefore play a key role in sculpting more-specific
cellular identities. If this is the case, we expect that purified subpopulations will reveal high
specificity of methylation at specific sites for particular cell types. Thus, the observation that
most CH sites with nonzero methylation are methylated in ~20 to 25% of sampled cells (fig.
S1H) could be explained by the heterogeneity of these brain circuits rather than by
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stochastic methylation within each cell. These conclusions obtained from our genome-wide,
base-resolution, cell type–specific DNA methylomes for brain cells through key stages of
development are the first steps toward unraveling the genetic program and experience-
dependent epigenetic modifications leading to a fully differentiated nervous system.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Methylcytosine in mammalian frontal cortex is developmentally dynamic and abundant
in CG and CH contexts
(A) Browser representation of mC and mRNA transcript abundance in human and mouse
frontal cortex and human ES cells. Chr2, chromosome 2. (B) mCH/CH within gene bodies
exhibits opposite correlation with gene expression in ES cells (ESC) and brain. Contours
show data point density, and red line shows smoothed mCH/CH as a function of mRNA.
a.u., arbitrary units. (C) Synaptic density (for mouse, per 100 μm2; for human, per 100 μm3)
and mC level in CG and CH contexts through development in mouse and human frontal
cortex. †Synaptic density quantitation from De Felipe et al. (27) and Huttenlocher and
Dabholkar (28). (D) DNA methyltransferase mRNA and protein abundance (mean ± SEM)
in mouse frontal cortex through development. FPKM, fragments per kilobase of exon per
million fragments mapped. (E) Fraction of cytosine base calls with each modification in
fetal and adult mouse frontal cortex. (F) Cortex mC level in CG and CH contexts throughout
mouse and human chromosome 12 in 100-kb bins smoothed with ~1-Mb resolution. CEN,
centrosome. (G) Transcript abundance, chromatin accessibility [8-week mouse cortex ChIP
input and DNaseI hypersensitivity (HS) normalized read density], and mC levels in 5-kb
bins at the mouse immunoglobulin VH locus. (H) Density (z) plot of 10-week mouse frontal
cortex mCH level (x) versus 8-week mouse cortex ChIP-input normalized read density (y)
for all 10-kb bins of the mouse genome.
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Fig. 2. mCH is positionally conserved and is the dominant form of DNA methylation in human
neurons
(A) Browser representation of mCG and mCH in NeuN+ and NeuN− cells. Human NeuN+/
NeuN− samples: R1, 53-year-old female; R2, 55-year-old male. Mouse NeuN+/NeuN−
samples: R1, 7-week males; R2, 6-week females; R3, 12-month females (not shown). (B)
Percentage of methylated base calls in each sequence context throughout the genome. (C)
Box and whisker plot of mCG and mCH level in neurons and glia at genomic regions bound
by Dnmt3a versus a random set. Whiskers indicate 1.5 times the interquartile range. (D)
mCH correlation between NeuN+ and NeuN− cells in mouse and human, measured in 10-kb
bins. (E) Browser representation of mCH sites in neurons. Scatter plots (right) show
consistent mCH/CH at all single sites in a 20-kb window overlapping the example region
(left). (F) Correlation analysis of methylation state at single sites between neurons and ES
cells in human and mouse. Correlation values are normalized by a simulation (62).
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Fig. 3. mCH is enriched in genes that escape X inactivation
(A) Browser representation showing mCH-hypermethylated female human and mouse genes
that escape X inactivation (shaded genes). (B) Box and whisker plots of gender differences
in promoter mCG and intragenic mCH in inactivated and escapee genes on human chrX. (C)
Scatter plot of gender differences in mCG and mCH in human chrX genes. Reported X
inactivated and escapee genes: *Carrel and Willard (49); §Sharp et al. (50); †predicted
escapee genes, and autosomal (Chr2) genes are indicated. (D) Discriminability analysis of
genes that escape female X inactivation using mC data, showing correct versus false
detection rate mapped for all possible mC/C thresholds.
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Fig. 4. Celltype–specific and developmental differences in mC between mouse neurons and glia
(A) Heat-map representation of 25,260 mouse genes organized in gene sets identified by k-
means clustering using normalized genic mCG and mCH levels in adult developmental and
NeuN+ and NeuN− samples. Left-hand plot shows mRNA abundance. (B) Enrichment or
depletion of each cluster for developmental and cell-type specific gene sets. n.s., not
significant (FET, FDR < 0.05). (C) mCG and mCH throughout gene body and flanking 100
kb for indicated gene sets. Transcript abundance (mRNA-Seq FPKM) over mouse
development is shown for the same gene sets. Color scales are as in (A).
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Fig. 5. hmCG is enriched within active genomic regions in fetal and adult mouse brain
(A) hmCG level in 6-week mouse frontal cortex for autosomes and ChrX. (B) Median
hmCG level within genomic features (error bars 32nd to 68th percentile). enh, enhancer. (C)
Median normalized hmCG throughout gene body and flanking 100 kb for indicated gene
sets. Bars show absolute hmCG/CG levels within gene bodies for each class. (D) mC and
hmC throughout gene body and flanking 100 kb for each. Transcript abundance (mRNA-Seq
FPKM) during mouse development is also shown (left).
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Fig. 6. Developmental and cell type–specific differential mCG
(A) Heat map of absolute mCG level in CG-DMRs identified between neurons and glia and
over development in mouse (left) and human (right). (B) Fraction of all CG-DMRs located
in distinct genomic features in mouse. (C) Enrichment or depletion of distinct cell type–
specific and developmental CG-DMR sets within genomic features from (B). (D and E)
Intersection of developmentally dynamic CG-DMRs and (D) DNaseI hypersensitive sites or
(E) enhancers in mouse brain in thousands. (F) Browser representation of mouse
developmentally dynamic CG-DMRs and quantification of local enrichment of chromatin
modifications, genome accessibility, and mC. (G) TAB-Seq reads showing fetal-specific
hmCG in the Fetal>Adult CG-DMR in mouse. (H) Proportion of mouse developmental CG-
DMRs where mCG/CG is significantly increased or decreased in Tet2 knockout mice. (I)
Distribution of mCG level difference between wild-type (WT) and Tet2 mutantat mouse
CG-DMRs. Significantly different DMRs are indicated by coloration.
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